Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$17.01 USD
-0.30 (-1.73%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $17.54 +0.53 (3.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PIRS 17.01 -0.30(-1.73%)
Will PIRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PIRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PIRS
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
PIRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for August 23rd
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
Other News for PIRS
Biotech Alert: Searches spiking for these stocks today
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?